Impact of a National Clinical Trial Nurse Navigation Service on Trial Enrollment for Patients with a Hematologic Malignancy

November 2020 Vol 11, No 11
Ashley Giacobbi, MSN, RN, ACNS-BC, AOCNS
Leukemia & Lymphoma Society,
Rye Brook, NY
Alissa Gentile, MSN, RN
Leukemia & Lymphoma Society,
Rye Brook, NY
Leah Szumita, MS, RN, CCRN, ACNS-BC
Leukemia & Lymphoma Society,
Rye Brook, NY

Background: Low enrollment rates for cancer clinical trials have been an ongoing barrier to scientific advances in oncology care. Average clinical trial participation rates are estimated to be as low as 8% nationally, with great variability based on demographics.1 Whereas studies have explored the benefit of patient navigation in improving trial enrollment and completion at an institutional and statewide level,2,3 the impact of an advanced practice clinical trial nurse navigation program on trial enrollment from a national vantage point has not yet been discussed in the literature. With more than 178,520 new cases of leukemia, lymphoma, and myeloma anticipated to be diagnosed in 2020, clinical trial participation in studies investigating new treatments for hematologic malignancies are more important than ever.4

Objective: To determine the impact of the Leukemia & Lymphoma Society (LLS) Clinical Trial Support Center (CTSC) nurse navigation services on clinical trial enrollment for adult and pediatric patients with hematologic malignancies and the perceived helpfulness of the service.

Methods: LLS created the CTSC in 2016 and expanded the advanced practice nursing (APN) staff in 2019. The CTSC is charged with providing a personalized, patient-centered navigation service to identify and connect patients with potential clinical trials while addressing barriers to enrollment and educating patients about clinical trials. The APN staff assesses the patient’s preferences, physical condition, medical history, insurance coverage, ability to travel, and financial barriers to provide an individualized list of appropriate clinical trials.

A retrospective online survey of 474 patients and caregivers who utilized the CTSC from May 2018 to April 2019 was conducted by RTI International on behalf of LLS from July 2019 to August 2019 utilizing a standardized tool.

Results: A 30% response rate for the online survey provided 142 partially or fully completed surveys. A majority of respondents were white (92%, n = 114/124) and reported having at least a 4-year college degree (71%, n = 89/126). Of patients and caregivers surveyed, 29.8% (n = 39/131) enrolled in a clinical trial after receiving assistance from the CTSC APN. Over half of the participants who enrolled in a trial noted the CTSC nurse navigator helped them find the trial in which they enrolled (55.9%, n = 19/34). Further, 99.2% (n = 130/131) of respondents found the conversation(s) with the CTSC nurse navigator to be helpful, and 98.5% (n = 128/130) reported the CTSC nurse navigator’s ability to answer questions as great or excellent.

Conclusion: Use of a nationally focused, advanced practice clinical trial nurse navigation program for hematologic malignancies facilitated clinical trial enrollment of 21%, well above the national estimate of trial participation of 8%. The vast majority of those who utilized the service found it helpful. Similar to noted disparities in nationwide clinical trial participation, there is lack of diversity among those historically served by the CTSC. LLS is actively working to improve the reach of this service into racially, ethnically, and socioeconomically diverse communities.


  1. American Cancer Society. Cancer Action Network. Barriers to Patient Enrollment in Therapeutic Clinical Trials for Cancer - A Landscape Report. 2018.
  2. Ghebre RG, Jones LA, Wenzel JA, et al. State-of-the-science of patient navigation as a strategy for enhancing minority clinical trial accrual. Cancer. 2014;120:1122-1130.
  3. Moffitt K, Brogan F, Brown C, et al. Statewide cancer clinical trial navigation service. J Oncol Pract. 2010;6:127-132.
  4. American Cancer Society. Cancer Facts & Figures 2020. 2020.
Related Articles
6-Month LHRH Formulations Are a Good Choice During the COVID-19 Pandemic and Beyond
Tina DeNofrio, RN, BSN, OCN, Stuart N. Atkinson, MB, ChB, Deborah M. Boldt-Houle, PhD
November 2021 Vol 12, No 11
Prostate cancer (PCa) patients treated with injectable androgen deprivation therapy (ADT) are particularly vulnerable during a pandemic because they may not be able to self-administer treatment and may be required to visit a clinic/hospital for injections.
A Virtual Prostate Cancer Clinic for Follow-Up Care: A Digital Health Platform Creates Efficient Navigation and Care Coordination Benefiting Survivors, Provider, and the Healthcare System
Richard N. Boyajian, Ashleigh M. Kowtoniuk, PA, APRN-NP, Krystle R. Boyajian, Mark J. Mackin, MBA, RT(T)
November 2021 Vol 12, No 11
Prostate cancer is the most common male malignancy. In 2021, the United States will see an estimated 248,530 new cases, 34,130 deaths, and more than 3 million survivors.
Creating an Electronic Referral to Help Identify Patients with Breast Cancer Needing Navigation Services
Melissa Douglas, BSN, RN, CBCN
November 2021 Vol 12, No 11
The oncology nurse navigator (ONN) plays a central role in decreasing distress and increasing satisfaction in patients with breast cancer.
Last modified: May 7, 2021

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State

    Please enter your mailing address.

    Address Line 2
    Zip Code